Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study

Rauch, AndriAndriRauch0000-0001-5297-6062Nolan, DDNolanMartin, AAMartinMcKinnon, EEMcKinnonAlmeida, CCAlmeidaMallal, SimonSimonMallal2024-10-132024-10-132006https://boris-portal.unibe.ch/handle/20.500.12422/93006Abacavir therapy is associated with significant drug hypersensitivity in approximately 8% of recipients, with retrospective studies indicating a strong genetic association with the HLA-B*5701 allele. In this prospective study, involving 260 abacavir-naive individuals (7.7% of whom were positive for HLA-B*5701), we confirm the usefulness of genetic risk stratification, with no cases of abacavir hypersensitivity among 148 HLA-B*5701-negative recipients.enProspective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort studyarticle10.7892/boris.192401675842400023803000001510.1086/504874